RxDoctor Payments Data

Aaron Lewis, MD

Surgical Oncology · South Pasadena, CANPI 1053542100

Payments from drug & device makers

What this record shows

This record is dominated by education: $6,072 of the $10,002 with a category attached, or 60.7%. Intuitive Surgical accounts for 88.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $4,191 and has fallen 77.3% since, to $952 in 2025.

$10,002in general payments, 2019–2025

Across 33 payments — averaging $303.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$9K
  • Integra Lifesciences Corporation$952
  • GSK$65
  • Amgen$59
  • Novartis$44
  • Johnson & Johnson$32
  • plus $40 from 2 others

What the payments were for

  • Travel & lodging$2,28123%
  • Food & beverage$6977%
  • Education$6,07261%
  • Other$95210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,002 in reported general payments places this provider in the 75th percentile of 209 surgical oncology providers in California.

See all surgical oncology providers in California

Medicare billing

Part B allowed, 2024
$307,637
Medicare patients
298
Services billed
921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase37$34,926
Neomycin Sulfate14$65
Metronidazole19$17

Paid to pharmacies, not to this prescriber.

Other surgical oncology in South Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →